Coya Therapeutics (NASDAQ:COYA) Trading Up 4.5% – Should You Buy?

Coya Therapeutics, Inc. (NASDAQ:COYA) shot up 4.5% during trading on Monday . The company traded as high as $8.29 and last traded at $7.40. 277,078 shares were traded during mid-day trading, an increase of 269% from the average session volume of 75,046 shares. The stock had previously closed at $7.08.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on COYA. Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, November 11th. Finally, D. Boral Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Thursday, February 6th.

Coya Therapeutics Trading Up 4.5 %

The business has a 50-day moving average price of $6.12 and a two-hundred day moving average price of $6.43. The stock has a market capitalization of $123.63 million, a P/E ratio of -11.38 and a beta of 0.47.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after buying an additional 4,485 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Coya Therapeutics during the fourth quarter worth $401,000. Jane Street Group LLC bought a new position in shares of Coya Therapeutics in the 4th quarter valued at $74,000. Northern Trust Corp lifted its position in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after buying an additional 3,099 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after buying an additional 4,777 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.